decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
National_Coverage_Determinations_Manual / FDG_PET_FOR_DEMENTIA_AND_NEURODEGENERATIVE_DISEASES
Subscribe or sign in to view the full article.
Article Overview
This National Coverage Determination article explains Medicare’s coverage framework for FDG-PET imaging in dementia-related evaluation. It focuses on the qualifying clinical context, required documentation and facility standards, and the distinction between routine covered use, clinical-trial-based use, and noncovered scenarios. It is most relevant for clinicians, radiology and nuclear medicine teams, dementia specialists, and billing/coding staff who need to understand the policy scope and documentation expectations.
Why This Topic Matters
Coverage policy determines when FDG-PET may be reimbursed under Medicare and what supporting records must be maintained. Understanding the policy helps providers align ordering, documentation, and trial participation with CMS requirements.
Article Sections
-
A. General
Introduces the overall Medicare coverage framework for FDG-PET in dementia and neurodegenerative disease evaluation. Summarizes the two broad coverage pathways addressed in the article.
-
B. Nationally Covered Indications
Describes the circumstances in which FDG-PET is covered and the general conditions that must be satisfied. Includes the main coverage pathway and the clinical-trial-based pathway.
-
1. FDG-PET Requirements for Coverage in the Differential Diagnosis of AD and FTD
Outlines the covered diagnostic context for distinguishing between Alzheimer’s disease and frontotemporal dementia. Covers evaluation, documentation, facility, and prior-study considerations at a high level.
-
2. FDG-PET Requirements for Coverage in the Context of a CMS-approved Practical Clinical Trial Utilizing a Specific Protocol to Demonstrate the Utility of FDG-PET in the Diagnosis, and Treatment of Neurodegenerative Dementing Diseases
Describes the trial-based coverage pathway for FDG-PET in selected patients with cognitive impairment or early dementia. Summarizes the basic trial oversight and protocol requirements.
-
C. Nationally Noncovered Indications
Identifies categories of FDG-PET use that are not covered under this policy. Provides the general scope of excluded uses.
-
D. Other
Contains brief closing administrative material and the review date of the policy.
What You Will Learn
- How Medicare frames coverage for FDG-PET in dementia-related evaluation
- Which broad clinical scenarios are addressed by the policy
- What types of documentation and oversight the policy emphasizes
- How covered use differs from trial-based use and noncovered use
- What general provider groups are affected by the policy
Who Should Read This
- Physicians evaluating dementia and neurodegenerative disease
- Nuclear medicine and radiology professionals
- Neurology and psychiatry clinicians
- Hospital compliance and revenue cycle staff
- Medical coders and billers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com